Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Apr 22, 2022
Institute will drive sustainable innovation in three areas of environmental stewardship, furthering progress toward the company's 2030+ environmental, social and governance (ESG) commitments...
-
Apr 7, 2022
BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will report financial results for its second quarter of fiscal year 2022 on Thursday, May 5, 2022. A news release will be...
-
Apr 1, 2022
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has completed its spinoff of Embecta Corp. (embecta) (NASDAQ: EMBC), which...
Mar 31, 2022BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Alberto Mas has informed the company of his intent to retire from BD, effective at...
-
Mar 30, 2022
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company today announced the early results and pricing terms of Morgan Stanley & Co. LLC's ("Morgan Stanley")...
Mar 30, 2022BD Rhapsody™ TCR/BCR Multiomic Assay speeds discovery in autoimmune disorders, immuno-oncology and infectious diseasesFRANKLIN LAKES, N.J. (Mar 30, 2022) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, recently released the BD Rhapsody™ TCR/BCR Multiomic Assay,...
-
Mar 25, 2022
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has been named to Newsweek's inaugural list of "America's Most Trusted...
-
Mar 21, 2022
Record date for spin-off is March 22, 2022 "When Issued" trading of embecta common stock is expected to begin on March 21, 2022, under the ticker "EMBCV" BD expects the spin-off of embecta to be...
-
Mar 16, 2022
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company today announced that Morgan Stanley & Co. LLC ("Morgan Stanley") has commenced cash tender offers (each,...
Mar 1, 2022BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of William "Bill" Brown to its board of directors, effective Feb. 28, 2022.
Feb 25, 2022FRANKLIN LAKES, N.J. and INDIANAPOLIS (Feb. 25, 2022) – USA Track & Field and BD, a leading global medical technology company, today announced the extension of BD’s sponsorship through 2022....
-
Feb 24, 2022
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will virtually present at the Cowen 42nd Annual Health Care Conference via...
Feb 23, 2022BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Shana Neal has been appointed chief people officer, effective April 4, 2022. Neal,...
Feb 23, 2022BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced that embecta, the diabetes care business that is expected to spin off from BD on April 1,...
Feb 22, 2022Company is No. 1 Best Large Employer in Health Care Equipment & Services IndustryFRANKLIN LAKES, N.J., Feb. 22, 2022 -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced that it ranked No. 1 in the Health Care Equipment &...
Feb 8, 2022Organizations including Superhuman Use BD Veritor™ At-Home COVID-19 Test with the ReturnSafe Platform to Keep Employees Safe at WorkBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration with ReturnSafe, the all-in-one software solution for COVID-19 employee...
-
Feb 3, 2022- Revenue of $5.0 billion declined 6.0% as reported and 5.9% on currency-neutral basis, due to a decline in worldwide COVID-only testing revenues to $185 million from $866 million in the prior year
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its first quarter of fiscal year 2022, which ended December 31, 2021. "Our...
Feb 1, 2022BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of directors has approved the planned spinoff of its diabetes care business,...
-
Feb 1, 2022Informatics Capabilities Help Expand BD Data Analytics Capabilities and Understanding of Cancer and Other Chronic Diseases
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has completed the acquisition of Cytognos, a privately held company headquartered in...
-
Jan 27, 2022Company Included in 2022 Bloomberg Gender-Equality Index and Named Best Place to Work for LGBTQ+ Equality from The Human Rights Campaign Foundation
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has been included in the 2022 Bloomberg Gender-Equality Index (GEI) for the...
Jan 26, 2022Study uses real-world data to demonstrate the effectiveness of vaginal panel performed on the BD MAX™ System compared to clinicians' assessmentsBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the outcome of a peer-reviewed study published in the journal of Obstetrics &...
-
Jan 25, 2022
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.87 per common share, payable on March 31, 2022 to holders of record on March 10,...
Jan 20, 2022Technology Breakthrough Has Potential to Transform Wide Range of Disciplines from Immunology and Genomics Research to Cell-Based TherapeuticsBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that a study conducted in collaboration with the European Molecular Biology Laboratory...
Jan 11, 2022JUST 100, the Only Ranking that Recognizes Companies Doing Right by All Their Stakeholders as Defined by the American Public, Acknowledges BD's Commitment to Environmental, Social and Governance PerformanceBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it was named to the JUST 100 list of America's most just companies by JUST Capital and...
Jan 11, 2022Joint Effort Will Highlight How Diagnostic Best Practices Can Improve Patient Care, Clinical Practice and Health Care EconomicsBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration with Pfizer Inc. and global charitable foundation Wellcome to better...
Jan 7, 2022BD Kiestra™ IdentifA Receives 510(K) Clearance for Automated Sample Processing and MALDI Target PreparationBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA)...
-
Jan 6, 2022
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that in the interest of the health and safety of its shareholders, directors, officers,...
Jan 6, 2022Highlights Company's Impact on Advancing Cybersecurity Maturity in Health CareBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today released its second annual cybersecurity report to update stakeholders on the state of health...
-
Jan 5, 2022
BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will report financial results for its first quarter of fiscal year 2022 on Thursday, Feb. 3, 2022. A news release will be...
-
Dec 22, 2021
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will virtually present at the 40th Annual J.P. Morgan Healthcare Conference via...
Dec 22, 2021Tests now available online through Everly Health and in-store at Winn-Dixie, Harveys Supermarket, and Fresco y MásBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical company, today announced the BD Veritor™ At-Home COVID-19 Test is now available for purchase through Everly Health, a...
-
Dec 21, 2021
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Embecta Corp. ("embecta"), the independent, publicly-traded company that will hold...
Dec 21, 2021Advances company's innovation focus on enabling new care settings and accelerating smart connected careBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has completed the acquisition of privately held Scanwell Health Inc., a leader in...
Dec 17, 2021BD COR™ MX for Infectious Disease Testing Receives CE Mark and is Final Instrument Introduced on BD COR™ SystemBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has expanded the BD COR™ System to include a new MX instrument for high-throughput...
Dec 15, 2021€70 Million Investment to Establish New Research Laboratories, Jobs in Software Engineering, Informatics and CybersecurityLIMERICK, IRELAND (15TH Dec. 2021) –BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced plans to create more than 130 new jobs and invest €
Dec 9, 2021Stamford, Conn. – Dec. 9, 2021 – The global medical technology company, BD (Becton, Dickinson and Company), has committed $500,000 to improve quality of care and reduce health inequities for...
Dec 9, 2021- Acquisition complements BD's core portfolio - adding an innovative, broadly applicable surgical sealant to a suite of BD biosurgery products already relied upon in the operating room.BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it has acquired Tissuemed, Ltd., a privately held firm headquartered in Leeds, England...
Dec 8, 2021Addition of 100 local jobs will play key role in bolstering manufacturing capacity to supply the market with pre-filled flush syringes for use in health care settingsDROGHEDA, IRELAND (December 8, 2021) – BD (Becton Dickinson and Company), a leading global medical technology company, held a ribbon cutting ceremony today to announce the creation of 100 new...
Dec 6, 2021BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that "embecta" [pronounced em-BECK-tah] will be the name of the independent,...
Dec 2, 2021- Acquisition marks BD's entry point to the treatment of Chronic Venous Insufficiency -- adding transformative solutions to its existing venous disease portfolio with the potential to reshape patient care.BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it has acquired Venclose, Inc., a provider of solutions for the treatment of chronic...
Dec 1, 2021Progress Builds Strong Foundation for Bold 2030+ ESG Goals to Advance the World of Health for AllBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the release of its 2021 Global Inclusion, Diversity and Equity (ID&E) Report. The...
-
Nov 30, 2021
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement regarding testing for the COVID-19 Omicron variant of concern....
Nov 29, 2021Digital Health Pioneer to Focus on External Innovation; Becomes Co-Chair of BD Scientific Advisory BoardBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Dr. Joseph M. Smith has been named senior vice president and chief scientific...
Nov 24, 2021BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced Francesca DeMartino has been named senior vice president of investor relations for the...
-
Nov 16, 2021New facility will expand BD’s capacity to supply the European market with pre-fillable syringes for use in applications such as vaccines and other biologic drugs; add 150 local jobs by 2024.
FRANKLIN LAKES, N.J. (November 16, 2021) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, broke ground on a €165 million ($200 million USD)...
Nov 12, 2021- Innovation agenda focuses on advancing human health through smart connected care, new care settings and chronic disease outcomesBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, will begin its Investor Day at 8 a.m. ET today to share how it plans to leverage the breadth and depth...
Nov 4, 2021- Fourth fiscal quarter revenues of $5.1 billion grew 7.3% on a reported basis or 5.9% on a currency-neutral basis.BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for the fourth fiscal quarter and full fiscal year ended September 30, 2021....
-
Nov 4, 2021
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.87 per common share, an increase of 4.8% from the previous quarter. The dividend...
Oct 28, 2021BARDA to Invest $24.7 Million for BD to Develop New Tests for Core Labs, Hospitals and Point-of-Care LocationsBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the formation of a strategic, public-private partnership with the Biomedical Advanced...
Oct 26, 2021Event will provide strategic update, with focus on company's innovation and growth agendasBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will host a virtual investor day on Friday, Nov. 12, 2021 at 8 a.m., which will...